
About MedinCell
MedinCell is a publicly listed company based in Jacou (France) founded in 2002. Drug delivery injectables for therapeutic treatments are developed. Its chief executive, as recorded, is Christophe Douat. MedinCell offers products and services including UZEDY, mdc-TJK, and mdc-CWM. Its focus areas include Life Sciences, Drug Delivery and Intravenous.
Company details
MedinCell was founded in 2002 in Jacou, France, and operates in the biotechnology sector focused on long-acting injectable drug delivery systems. Products under development include a subcutaneous injection for schizophrenia in phase III trials, an intra-articular injection for pain and inflammation in phase II, and a preclinical subcutaneous option for schizophrenia. Six additional injectables target various diseases, with operations centered on clinical advancement and formulation.
- Headquarters Jacou, France
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Email••••••••
- Website medincell.com
- Social LinkedIn X Facebook YouTube
- Legal Name Medincell Sa
- Annual Revenue$22.44 M (USD)-23.21as on Mar 31, 2026
- Net Profit-$35.98 M (USD)-69.69as on Mar 31, 2026
- EBITDA-$27.22 M (USD)-111.24as on Mar 31, 2026
- Latest Funding Round$44.12M (USD), Post-IPO
Feb 2025
- InvestorsGates Foundation
& 8 more
Products & Services of MedinCell
MedinCell offers a comprehensive portfolio of products and services, including UZEDY, mdc-TJK, and mdc-CWM.
Long-acting injection for schizophrenia relapse prevention
Once-monthly subcutaneous injection for schizophrenia
Intraarticular therapy for post-operative pain relief
Apps and channels of MedinCell
its YouTube channel MedinCell has 243 subscribers and 30 videos.
Videos from MedinCell
The most watched videos on MedinCell's YouTube channel, MedinCell (243 subscribers). Click a video to play it here.
More on MedinCell.
Funding Insights of MedinCell
- Total Rounds 6
- Last Round Post-IPO — $44.12M
- Investors Count 9
All 6 funding rounds of MedinCell with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2025 | $44.12M | Post-IPO | – | – | |
| May 2023 | $27.45M | Post-IPO | – | – | – |
| Nov 2019 | $4.75M | Grant | – | – | |
| Mar 2018 | $24.64M | Debt – Conventional | – | – | |
| Nov 2017 | $3.5M | Grant | – | – | |
| Oct 2017 | Private Equity Round | – | Credit Mutuel Equity | – |
9 investors in total: 9 institutional.
Investors in MedinCell
MedinCell has secured backing from 9 investors, including institutional and venture fund investors. Prominent investors backing the company include Gates Foundation, European Investment Bank and Mirova.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments in equities, bonds, infrastructure, and impact projects are managed. | 2012 | mirova.com | Paris, France | |
Finance and advisory services for infrastructure projects are provided. | 1958 | eib.org | Luxembourg, Luxembourg | |
Growth and acquisition investments are managed by Credit Mutuel Equity. | creditmutuel-equity.eu | Paris, France | ||
Offers investment management and secure information access to clients and partners. | 2001 | adagecapital.com | Boston, United States | |
Diversified investment management services are provided to institutional clients. | wellington.com | Boston, United States | ||
Independent asset manager offering Event Driven equity funds for absolute performance. | 2009 | syquant-capital.fr | Paris, France | |
Aircraft for military, civil, and space applications are manufactured. | 1916 | dassault-aviation.com | Saint Cloud, France | |
It serves as a polar capital | home. | polarcapitals.co.uk | United Kingdom | ||
Charitable foundation investments on poverty reduction and healthcare | 2000 | gatesfoundation.org | Seattle, United States |
Investor details for MedinCell
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of MedinCell
45 people are tracked at MedinCell (15 in leadership, 4 in board & advisors, 26 in team).
| Name | Role | Group |
|---|---|---|
Christophe Douat | CEO | Leadership |
E. Louise Lagerqvist Ph.D. | Director, Partnering | Leadership |
Christophe Roberge | Chief Technical Officer | Leadership |
Sébastien Enault | Chief Business Officer | Leadership |
Franck Pouzache | Chief People Officer | Leadership |
Quiterie De Beauregard | Head, Portfolio | Leadership |
Adolfo Lopez Noriega | Research Director | Leadership |
Nathalia Murillo | Head Of Alliances | Leadership |
Richard Malamut | Chief Medical Officer At Medincell, Inc, Montpellier, France | Leadership |
Stéphane Chambaud | Head Of Pharmaceutical Operations | Leadership |
Stephane Postic | Chief Financial Officer | Leadership |
Grace Kim | Chief Strategy Officer, U.s. Finance | Leadership |
Guillaume Badoc | Chief Accountant | Leadership |
Sohei Fukuyama | Head Of Business Development And Licensing | Leadership |
Sylvestre Grizot | Research Director | Leadership |
Philippe Guy | Supervisory Board Member | Board & advisors |
Virginie Lleu | Supervisory Board Member | Board & advisors |
Anh Nguyen | Chairman | Board & advisors |
Sabri Markabi | Vice Chairman | Board & advisors |
Francesco Ravalico | Formulation Team Leader | Team |
25 more people are available in the full profile.
Complete people profiles for MedinCell
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of MedinCell
MedinCell is a publicly listed company on the EURONEXT with ticker symbol MEDCL in France, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Aug 2018
- Listed onEuronext: MEDCL
- Listed entityMedinCell SA
- Exchange sectorHealth technology
- ISINFR0004065605
- Share price26.44 EUR (-0.53% on the day) · 2026-10-14
- Market capitalisation954,768,555.00 EUR
- EPS (diluted, trailing year)-0.94 EUR
- Volume (last session)17,788
Financials of MedinCell
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 19.5M EUR | -31.3M EUR | -23.7M EUR |
| 2024 | 25.4M EUR | -18.4M EUR | -11.2M EUR |
| 2023 | 9.0M EUR | -25.0M EUR | -22.2M EUR |
| 2022 | 9.9M EUR | -32.0M EUR | -26.2M EUR |
| 2021 | 4.1M EUR | -24.8M EUR | -26.6M EUR |
Detailed financial statements for MedinCell
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of MedinCell
4 dated milestones of MedinCell across 23 years, from founding to its latest funding, stage changes and deals.
- Founded MedinCell is founded.
- Funding First funding round.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $44.1M.
Web traffic of MedinCell
The website of MedinCell (medincell.com) receives about 8.5K visits a month and ranks #1,508,006 among all websites worldwide, #1,990 in Biotechnology and Pharmaceuticals.
- Monthly visits8.5K
▼ 29.4% vs previous month
- Unique visitors4.4K
per month
- Global rank#1,508,006
among all websites
- Category rank#1,990
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit3.8
- Average visit9 min 37 sec
- DevicesDesktop 27% · Mobile 73%
Websites whose visitors overlap most with MedinCell. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| eurobiomed.org | 100% | 6K | #3,161,400 | View details | |
| medicinova.com | 97% | 3.5K | #5,782,921 | View details | |
cowurine.com | cowurine.com | 52% | #1,890,255 | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Medincell
Complete news archive for MedinCell
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about MedinCell
MedinCell was founded in 2002 and raised its 1st funding round 15 years after it was founded.
MedinCell is headquartered in Jacou, France. It is registered at Jacou, Herault, France.
Christophe Douat is the CEO of MedinCell, as recorded in our data.
Annual revenue of MedinCell is $22.44M as on Mar 31, 2026.
MedinCell was founded in 2002 in Jacou, France, and operates in the biotechnology sector focused on long-acting injectable drug delivery systems. Products under development include a subcutaneous injection for schizophrenia in phase III trials, an intra-articular injection for pain and inflammation in phase II, and a preclinical subcutaneous option for schizophrenia. Six additional injectables target various diseases, with operations centered on clinical advancement and formulation.
MedinCell offers UZEDY, mdc-TJK, and mdc-CWM.
Yes, MedinCell is publicly traded on EURONEXT under the ticker symbol MEDCL.
MedinCell has 9 investors. Key investors include Gates Foundation, European Investment Bank, Mirova, Dassault Aviation, and Adage Capital Management.
